Dermata Therapeutics, Inc. (DRMAW) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
3525 Del Mar Heights Road
San Diego, CA 92130
United States of America (the)
Phone
858 800 2543
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
August 13, 2021
| Name | Title | Pay | Year Born |
| Gerald T. Proehl | Founder, President, Chief Executive Officer & Chairman | 420,000 | 1959 |
| Maria Bedoya Toro Munera | Senior Vice President of Regulatory Affairs & Quality Assurance | 27,040 | 1951 |
| David F. Hale | Co-Founder & Lead Independent Director | 73,000 | 1949 |
| Kyri K. Van Hoose | Senior Vice President & Chief Financial Officer | 485,195 | 1978 |
| Christopher J. Nardo | Senior Vice President & Chief Development Officer | 513,765 | 1965 |
| Sean Proehl | Associate General Counsel | 0 | N/A |
| Kyra Peckaitis | Vice President of Marketing | 0 | N/A |
Dermata Therapeutics, Inc., a biotechnology company in the clinical development stage, is headquartered in San Diego, California, and was established in 2014. The firm's core mission is to develop innovative treatments for a variety of dermatological and cosmetic skin conditions. Its flagship investigational product, DMT310, is a topical formula applied once weekly that is currently undergoing clinical trials. This primary compound is being evaluated for its effectiveness against acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. Additionally, the company is advancing DMT410, which is intended to address hyperhidrosis (excessive sweating) and other aesthetic concerns.